MDCP vs. CNCR ETF Comparison

Comparison of VictoryShares THB Mid Cap ESG ETF (MDCP) to Loncar Cancer Immunotherapy ETF (CNCR)
MDCP

VictoryShares THB Mid Cap ESG ETF

MDCP Description

Victory Portfolios II - VictoryShares THB Mid Cap ESG ETF is an exchange traded fund launched and managed by Victory Capital Management Inc. The fund invests in public equity markets across global region. It invests in stocks of companies operating across diversified sectors. The fund invests in growth and value stocks of mid-cap companies, within the market capitalization range of the Russell Mid Cap Index. It invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. It employs fundamental and quantitative analysis with bottom-up stock picking approach to create its portfolio. The fund does not invest in companies operating across manufacture of complete tobacco products, cluster munitions, thermal coal and fossil fuels sectors. It employs internal, external and proprietary research to create its portfolio. Victory Portfolios II - VictoryShares THB Mid Cap ESG ETF is domiciled in the United States.

Grade (RS Rating)

Last Trade

$27.49

Average Daily Volume

13,082

Number of Holdings *

30

* may have additional holdings in another (foreign) market
CNCR

Loncar Cancer Immunotherapy ETF

CNCR Description ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.

Grade (RS Rating)

Last Trade

$15.20

Average Daily Volume

36,827

Number of Holdings *

71

* may have additional holdings in another (foreign) market
Performance
Period MDCP CNCR
30 Days 2.68% 4.32%
60 Days -1.15% -4.94%
90 Days 2.17% -6.86%
12 Months 18.71% 15.33%
0 Overlapping Holdings
Symbol Grade Weight in MDCP Weight in CNCR Overlap
MDCP Overweight 30 Positions Relative to CNCR
Symbol Grade Weight
APH B 5.28%
HEI B 4.59%
NVR D 4.45%
CSL B 4.08%
CACI B 4.0%
DHI D 3.93%
ROL C 3.86%
WAB A 3.83%
FAST D 3.71%
PTC C 3.63%
CHE F 3.34%
NEU D 3.29%
POOL D 3.29%
ROST D 3.28%
ANSS D 3.28%
GGG D 3.26%
PCAR D 3.25%
CF F 3.23%
GWW D 3.21%
HOLX D 3.2%
WST F 2.95%
TDY D 2.93%
LFUS C 2.72%
DAR D 2.68%
TTC D 2.63%
CPRT D 2.63%
ODFL F 2.57%
KEYS C 2.37%
JBHT F 2.31%
LSTR C 2.24%
MDCP Underweight 71 Positions Relative to CNCR
Symbol Grade Weight
GERN C -2.9%
ELVN C -2.71%
ACRV C -2.1%
CGEM C -2.1%
DCPH A -2.09%
NUVB C -1.99%
JANX C -1.8%
BPMC C -1.62%
HCM C -1.62%
LYEL C -1.59%
RVMD B -1.53%
DAWN C -1.51%
ITOS B -1.49%
TSVT D -1.47%
STRO D -1.42%
MRK B -1.41%
XNCR C -1.4%
BCYC D -1.34%
REGN B -1.33%
SMMT C -1.32%
AURA F -1.32%
MRUS D -1.32%
IPHA C -1.31%
TYRA C -1.31%
INBX D -1.3%
BNTX D -1.3%
IGMS D -1.3%
NRIX C -1.3%
MOR B -1.3%
IMCR F -1.3%
KYMR D -1.28%
VOR F -1.28%
FHTX F -1.28%
SNDX D -1.27%
EXEL F -1.26%
KURA C -1.24%
IOVA F -1.24%
GMAB D -1.24%
ERAS F -1.23%
MGNX F -1.2%
IDYA D -1.19%
PRLD D -1.19%
SDGR F -1.18%
PGEN D -1.18%
IMTX D -1.16%
ZNTL F -1.16%
RCUS D -1.15%
DNA F -1.14%
SWTX D -1.14%
BMY F -1.12%
YMAB F -1.12%
GLUE F -1.11%
NUVL D -1.05%
RXRX C -1.05%
ACET F -1.04%
KPTI D -1.04%
RLAY F -1.01%
REPL F -1.0%
ACLX D -0.99%
AUTL F -0.96%
ARVN D -0.93%
RPTX F -0.91%
LEGN F -0.9%
BMEA F -0.89%
CRBU F -0.89%
GNLX F -0.84%
ALLO F -0.83%
RAPT F -0.72%
FATE F -0.71%
IMRX F -0.7%
MRSN F -0.64%
Compare ETFs